Microvessel density and endothelial cell proliferation levels in colorectal liver metastases from patients given neo‐adjuvant cytotoxic chemotherapy and bevacizumab

The treatment of patients with colorectal liver metastasis has improved significantly and first line therapy is often combined chemotherapy and bevacizumab, although it is unknown who responds to this regimen. Colorectal liver metastases grow in different histological growth patterns showing differe...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2016-04, Vol.138 (7), p.1777-1784
Main Authors: Eefsen, Rikke Løvendahl, Engelholm, Lars, Willemoe, Gro L., Van den Eynden, Gert G., Laerum, Ole Didrik, Christensen, Ib Jarle, Rolff, Hans Christian, Høyer‐Hansen, Gunilla, Osterlind, Kell, Vainer, Ben, Illemann, Martin
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Adenocarcinoma - mortality
Adenocarcinoma - pathology
Aged
Amputation
Angiogenesis
Angiogenesis Inhibitors - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bevacizumab - therapeutic use
Cancer
Cell growth
Cell Proliferation - drug effects
Chemotherapy
Chemotherapy, Adjuvant
colorectal cancer
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - mortality
Colorectal Neoplasms - pathology
Denmark
Endothelial Cells - drug effects
Female
growth pattern
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Ki67
Liver
liver metastasis
Liver Neoplasms - drug therapy
Liver Neoplasms - secondary
Male
Medical research
Metastasis
microvessel density
Middle Aged
Neoadjuvant Therapy
Neovascularization, Pathologic - drug therapy
Neovascularization, Pathologic - pathology
Proportional Hazards Models
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The treatment of patients with colorectal liver metastasis has improved significantly and first line therapy is often combined chemotherapy and bevacizumab, although it is unknown who responds to this regimen. Colorectal liver metastases grow in different histological growth patterns showing differences in angiogenesis. To identify possible response markers, histological markers of angiogenesis were assessed. Patients who underwent resection of colorectal liver metastasis at Rigshospitalet, Copenhagen, Denmark from 2007 to 2011 were included (n = 254) including untreated and patients treated with chemotherapy or chemotherapy plus bevacizumab. The resected liver metastases were characterised with respect to growth pattern, endothelial and tumour cell proliferation as well as microvessel density and tumour regression. Tumour regression grade of liver metastases differed significantly between untreated/chemotherapy treated patients in comparison to chemotherapy plus bevacizumab treated patients (both p 
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.29904